Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti ‐Rheumatic Drugs (DMARDs): a Systematic Review and Meta‐analysis

ConclusionWe found the hepatitis B reactivation rate in inflammatory arthritis patients receiving DMARDs was low in resolved patients and moderate in chronic HBV infection patients. Further, lower rates were observed in chronic HBV infection patients using antiviral prophylaxis.This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - August 22, 2017 Category: Rheumatology Authors: Tzu ‐Chieh Lin, Kazuki Yoshida, Sara K. Tedeschi, Mirhelen Mendes Abreu, Nikroo Hashemi, Daniel H. Solomon Tags: Original Article Source Type: research